NASDAQ:COYA Coya Therapeutics (COYA) Stock Price, News & Analysis $5.08 -0.10 (-1.93%) Closing price 09/25/2026 04:00 PM EasternExtended Trading$5.07 -0.01 (-0.20%) As of 09/25/2026 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Coya Therapeutics Stock (NASDAQ:COYA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Coya Therapeutics alerts:Sign Up Key Stats Today's Range$5.02▼$5.2450-Day Range$3.87▼$5.3052-Week Range$3.71▼$7.75Volume59,938 shsAverage Volume144,313 shsMarket Capitalization$119.18 millionP/E RatioN/ADividend YieldN/APrice Target$15.33Consensus RatingModerate Buy Company Overview Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies designed to enhance the function of regulatory T cells, or Tregs. Tregs help regulate immune responses and may play a role in limiting inflammation associated with neurodegenerative and autoimmune diseases. The company’s pipeline includes investigational Treg-based therapies, including COYA 301, an autologous Treg therapy being evaluated for potential use in conditions such as amyotrophic lateral sclerosis (ALS). Coya is also developing combination approaches intended to improve Treg activity and persistence, including programs involving low-dose interleukin-2. Its candidates remain experimental and are subject to clinical and regulatory evaluation. Headquartered in Houston, Texas, Coya Therapeutics became a publicly traded company through a business combination with Nicoya Healthcare in 2023. The company’s development strategy is centered on advancing its proprietary Treg-focused platform for diseases in which chronic inflammation and impaired immune regulation may contribute to disease progression.AI Generated. May Contain Errors. Read More Coya Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks44th Percentile Overall ScoreCOYA MarketRank™: Coya Therapeutics scored higher than 44% of companies evaluated by MarketBeat, and ranked 636th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingCoya Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on no strong buy ratings, 6 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialCoya Therapeutics has a consensus price target of $15.33, representing about 201.8% upside from its current price of $5.08.Amount of Analyst CoverageCoya Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Coya Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Coya Therapeutics are expected to decrease in the coming year, from ($1.34) to ($1.92) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Coya Therapeutics is -4.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Coya Therapeutics is -4.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCoya Therapeutics has a P/B Ratio of 2.47. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Coya Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.39% of the float of Coya Therapeutics has been sold short.Short Interest Ratio / Days to CoverCoya Therapeutics has a short interest ratio ("days to cover") of 10.24, which indicates bearish sentiment.Change versus previous monthShort interest in Coya Therapeutics has recently increased by 9.41%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCoya Therapeutics does not currently pay a dividend.Dividend GrowthCoya Therapeutics does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.61 News SentimentCoya Therapeutics has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Coya Therapeutics this week, compared to 3 articles on an average week.Search Interest1 people have searched for COYA on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Coya Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Coya Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders6.10% of the stock of Coya Therapeutics is held by insiders.Percentage Held by Institutions39.75% of the stock of Coya Therapeutics is held by institutions.Read more about Coya Therapeutics' insider trading history. Receive COYA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Coya Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. COYA Stock News HeadlinesAnalyzing Coya Therapeutics (NASDAQ:COYA) and Zealand Pharma A/S (OTCMKTS:ZLDPF)September 21, 2026 | americanbankingnews.comBTIG Research Reiterates "Buy" Rating for Coya Therapeutics (NASDAQ:COYA)September 17, 2026 | americanbankingnews.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.September 26 at 1:00 AM | Stansberry Research (Ad)Coya Therapeutics Announces Enrollment of 100th Participant in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALSSeptember 15, 2026 | finance.yahoo.comCoya Therapeutics Advances COYA 302 ALS Phase 2/3 TrialSeptember 15, 2026 | tipranks.comCoya Therapeutics Announces Enrollment of 100th Participant in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALSSeptember 15, 2026 | businesswire.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Capricor Therapeutics (CAPR), Ansell (OtherANSLF) and Erasca (ERAS)August 26, 2026 | theglobeandmail.comExperimental ALS treatment being tested in Philadelphia: "There's potential here for a home run"August 13, 2026 | msn.comSee More Headlines COYA Stock Analysis - Frequently Asked Questions How have COYA shares performed this year? Coya Therapeutics' stock was trading at $5.80 at the beginning of 2026. Since then, COYA stock has decreased by 12.4% and is now trading at $5.08. How were Coya Therapeutics' earnings last quarter? Coya Therapeutics, Inc. (NASDAQ:COYA) announced its earnings results on Tuesday, August, 11th. The company reported ($0.28) EPS for the quarter, beating analysts' consensus estimates of ($0.35) by $0.07. The company earned $0.24 million during the quarter, compared to analyst estimates of $0.13 million. Coya Therapeutics had a negative net margin of 270.22% and a negative trailing twelve-month return on equity of 52.05%. When did Coya Therapeutics IPO? Coya Therapeutics (COYA) raised $15 million in an initial public offering (IPO) on Thursday, December 29th 2022. The company issued 3,050,000 shares at a price of $5.00 per share. Who are Coya Therapeutics' major shareholders? Top institutional investors of Coya Therapeutics include Long Corridor Asset Management Ltd (0.17%), Squarepoint Ops LLC (0.14%), AXQ Capital LP (0.08%) and Allworth Financial LP (0.06%). Insiders that own company stock include David S Snyder, Arun Swaminathan and Fred Grossman. View institutional ownership trends. How do I buy shares of Coya Therapeutics? Shares of COYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Coya Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Coya Therapeutics investors own include Broadcom (AVGO), NVIDIA (NVDA), Arista Networks (ANET), Disc Medicine (IRON), Jabil (JBL), Adobe (ADBE) and e.l.f. Beauty (ELF). Company Calendar Last Earnings8/11/2026Today9/26/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 COYA's financial health is in the Green zone, according to TradeSmith. COYA has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:COYA CIK1835022 Webwww.coyatherapeutics.com Phone(650) 739-3939FaxN/AEmployees8Year Founded2016Price Target and Rating Average Price Target for Coya Therapeutics$15.33 High Price Target$18.00 Low Price Target$12.00 Potential Upside/Downside+201.8%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($1.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$21.23 million Net Margins-270.22% Pretax Margin-270.18% Return on Equity-52.05% Return on Assets-46.34% Debt Debt-to-Equity RatioN/A Current Ratio13.40 Quick Ratio13.40 Sales & Book Value Annual Sales$7.95 million Price / Sales14.99 Cash FlowN/A Price / Cash FlowN/A Book Value$2.06 per share Price / Book2.47Miscellaneous Outstanding Shares23,460,000Free Float22,027,000Market Cap$119.18 million OptionableNot Optionable Beta0.61 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:COYA) was last updated on 9/26/2026 by MarketBeat.com Staff. From Our PartnersA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredIran War WARNING: Something Just ChangedA powerful Middle Eastern government is reportedly asking Trump for U.S. military help against Iran backed for...Banyan Hill Publishing | SponsoredBuffett's Final Warning: "The Dollar Is Going to Hell"On May 3rd, 2025, Warren Buffett looked at his shareholders for the last time and said: "The dollar is going t...Decentralized Masters | Sponsored"How Much Can I Actually Spend Each Year With $2.5M Saved?"Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...SmartAsset | Sponsored6 Elon Musk companies. The 1 FREE investor roadmap to them all.Elon Musk owns six companies, but most investors can only access four. Tesla, SpaceX, xAI, and X are public an...Zacks | SponsoredThe No. 1 move you need to make before Musk’s “Starphone” goes mainstreamTech forecaster Josh Baylin, who briefed Congress on the iPhone years before its release, says Elon Musk is bu...Stansberry Research | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredHow to get a stake in Anthropic — before the IPOAnthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coya Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coya Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
